T.TO 0.13ENB.TO 0.8BEP.UN.TO -1.15CP.TO 1.15VRT -19.67NVDA -7.33TSM -15.23JPM -6.1
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.72
-0.00 (0.00%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
HOLD

Pfizer Inc(PFE)

Mar 13, 2012
Prefers Teva to Pfizer. PFE does not have the growth profile. 11 or 12 times earnings. Abbot labs are good too. If it falls 10% he would be all over it.
Photo of Barry SchwartzBarry Schwartz
No
Unlock Rating
$22.01

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Feb 13, 2012
(A Top Pick Feb 28/11. Up 13.97%.)
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$21.30

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 02, 2012
Dividend is safe, growth prospects of many of the large Parma are very muted.
Photo of Don LatoDon LatoUnlock Rating
$21.11

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 01, 2012
Pharma: The trend is really looking quite good. Hasn’t looked at Pfizer in a while. There was a time when it was 0% return for 10 years. Now, it is in the right sector and it is moving.
Photo of Mike S. Newton, CIM FCSIMike S. Newton, CIM FCSIUnlock Rating
$21.31

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Jan 26, 2012
One of the defensive stocks that did very, very well last year. Starting to see it roll over a little bit. Technically speaking it still looks pretty sound with the 200 day moving upwards and the 50 day moving across the 200 day very recently. Dividend is about 4%. Doesn't look at this as a tremendous growing company but is in the mid to high single digit range.
Photo of Stan WongStan Wong
No
Unlock Rating
$21.63

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 09, 2012
(Market Call Minute.) Good dividend yield. Company is buying back a lot of stocks. Well-run in a very tough business.
Photo of John O'Connell, CFAJohn O'Connell, CFAUnlock Rating
$21.82

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 04, 2012
His model price is $26.88, which is a 22% positive differential. Yielding 4%. This happens to be one that has valuation and yield together, which is great. His target would be about $26.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$21.77

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 23, 2011
Pharmaceutical space is tough. Lipitor is a drug that is going off-patent which will reduce their income.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$18.45

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 21, 2011
The 3 sectors hated sectors in the US are financials, healthcare and technology. They have done a lot of smart things recently. They increased the dividend and announced a share buyback. Valuation is quite cheap and he is looking at this one.
Photo of Barry SchwartzBarry Schwartz
No
Unlock Rating
$18.96

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Nov 15, 2011
A good space. Defensive name. Prefers JNJ. Seeing higher lows this year. Could come down to a higher low. Ranked 5th on his list. Would hold it.
Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSIUnlock Rating
$19.87

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Oct 24, 2011
The whole pharma business is challenged. PFE is predicting lower revenues next year. Management is talking about breaking up the company. With Lipitor patent expiring, he would just sell it.
Photo of Gordon ReidGordon ReidUnlock Rating
$19.36

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 12, 2011
Suffering from loosing their patent on lipitor. Will be a pullback on earnings. Trying to reassess their businesses and potentially spinning some off. Not a big fan of large cap Pharma. Prefers diversified health care companies like Abbot.
Photo of Christine PooleChristine PooleUnlock Rating
$18.82

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 23, 2011
Debt rating cut but it doesn’t matter to him. They all have the patent cliff. He likes that they bought Wyeth who have a lot of drugs on patent. People say PFE is too big to make a difference if a new drug comes along so they are shrinking the company. Big, safe dividends.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$17.45

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 28, 2011
Lipitor is coming off patent and accounts for a boat 20% of their revenues. Sales are expected to drop about 5% next year.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$19.36

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Jul 22, 2011
Largest drug company in the world. Good pipeline, but they have been paring it down to focus on new drugs. Prefers Teva.
Photo of Richard FoglerRichard Fogler
No
Unlock Rating
$20.07

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 421 to 435 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

TPZ.TO 0.13$12.73
KBL.TO 0.98$42.9
PPL.TO -0.14$66.12
AQN.TO 0.11$7.46
EMA.TO -0.02$68.17

Today's Top Picks

T.TO 0.13$12.73
ENB.TO 0.8$67.03
BEP.UN.T… -1.15$40.98
CP.TO 1.15$124.99
VRT -19.67$237.39

Popular Articles

Latest Sell Signals

CPX.TO 1.15$124.99
AVGO -17.27$344.72
APP 10.28$334.24
XRE.TO 0.05$15.73
ORCL -5.49$144.79

Most Recent Experts

Ryan Bushell

Ryan Bushell

Newhaven Asset Management

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like